Literature DB >> 9146656

Neurogenic bladder dysfunction due to myelomeningocele: neonatal versus childhood treatment.

H Y Wu1, L S Baskin, B A Kogan.   

Abstract

PURPOSE: We sought to determine whether the neonatal institution of treatment of neurogenic bladder dysfunction in myelomeningocele patients at high risk for urinary tract deterioration improves renal and bladder outcome.
MATERIALS AND METHODS: We reviewed the records of patients with bladder dysfunction believed to be at high risk for renal deterioration based on urodynamic studies. All patients were treated with clean intermittent catheterization. We compared rates of urinary infection, hydronephrosis, reflux, continence and surgical intervention in 46 patients in whom treatment was started in year 1 of life and 52 treated after age 4 years.
RESULTS: Renal outcome was similar in both groups with persistent hydronephrosis in 6 of 46 patients (13%) and 7 of 52 (14%), respectively. However, significantly fewer bladder augmentation procedures were required in patients started on treatment during year 1 of life (5 of 46, 11% versus 14 of 52, 27%, p < 0.05).
CONCLUSIONS: In addition to any psychological benefit, early intervention with clean intermittent catheterization in children with neurogenic bladder dysfunction may help to prevent irreversible bladder dysfunction and limit the need for bladder augmentation.

Entities:  

Mesh:

Year:  1997        PMID: 9146656

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  [Myelomeningocele--"the next years..."].

Authors:  I Körner; A Reuss; U Kuhn; H Wiedemayer; D Stolke; J Pförtner; F A Löer; W Rösch; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Regenerative medicine strategies for treatment of neurogenic bladder.

Authors:  Roberto Soler; Claudius Fullhase; Anthony Atala
Journal:  Therapy       Date:  2009

3.  Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.

Authors:  Iraj Mirzaii-Dizgah; Bahram Salmanyan
Journal:  Eur Spine J       Date:  2013-08-02       Impact factor: 3.134

Review 4.  Early Vs. Expectant Management of Spina Bifida Patients-Are We All Talking About a Risk Stratified Approach?

Authors:  Angelena B Edwards; Micah Jacobs
Journal:  Curr Urol Rep       Date:  2019-11-16       Impact factor: 3.092

Review 5.  [Neurogenic bladder function disorders in patients with meningomyelocele: S2k guidelines on diagnostics and therapy].

Authors:  R Stein; C Assion; R Beetz; M Bürst; R Cremer; A Ermert; M Goepel; E Kuwertz-Bröking; B Ludwikowski; T Michael; J Pannek; H Peters; D Rohrmann; I Rübben; A Schröder; R Trollmann; J W Thüroff; W Wagner
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

6.  Renal cortical deterioration in children with spinal dysraphism: analysis of risk factors.

Authors:  Sean M DeLair; Jonathan Eandi; Marina J White; Thuan Nguyen; Anthony R Stone; Eric A Kurzrock
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

Review 7.  [Urological problems in patients with meningomyelocele. Diagnostic studies and management].

Authors:  R Stein; A Schröder; R Beetz; A Ermert; D Filipas; M Fisch; M Goepel; I Körner; B Schönberger; C Sparwasser; M Stöhrer; J W Thüroff
Journal:  Urologe A       Date:  2007-12       Impact factor: 0.639

8.  Pediatric enterocystoplasty: long-term complications and controversies.

Authors:  Eric A Kurzrock
Journal:  World J Urol       Date:  2008-10-10       Impact factor: 4.226

9.  Bladder Function After Fetal Surgery for Myelomeningocele.

Authors:  John W Brock; Michael C Carr; N Scott Adzick; Pamela K Burrows; John C Thomas; Elizabeth A Thom; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Diana L Farmer; Earl Y Cheng; Bradley P Kropp; Anthony A Caldamone; Dorothy I Bulas; Susan Tolivaisa; Laurence S Baskin
Journal:  Pediatrics       Date:  2015-10       Impact factor: 7.124

10.  Meningomylocele: An update.

Authors:  R Kapoor; S Agrawal
Journal:  Indian J Urol       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.